Compare WAVE & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | TNXP |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 198.6M |
| IPO Year | 2021 | 2008 |
| Metric | WAVE | TNXP |
|---|---|---|
| Price | $8.83 | $15.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 20.8K | ★ 352.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $436.84 | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $4.52 | $11.60 |
| 52 Week High | $9.85 | $69.65 |
| Indicator | WAVE | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 64.47 | 62.15 |
| Support Level | $6.99 | $14.93 |
| Resistance Level | $9.67 | $17.00 |
| Average True Range (ATR) | 0.74 | 1.04 |
| MACD | 0.09 | 0.21 |
| Stochastic Oscillator | 81.38 | 94.99 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.